<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002835</url>
  </required_header>
  <id_info>
    <org_study_id>MDA DM95-121</org_study_id>
    <secondary_id>P30CA016672</secondary_id>
    <secondary_id>MDA-DM-95121</secondary_id>
    <secondary_id>NCI-V96-1010</secondary_id>
    <secondary_id>CDR0000065044</secondary_id>
    <nct_id>NCT00002835</nct_id>
    <nct_alias>NCT00038740</nct_alias>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Patients With Lymphoma</brief_title>
  <official_title>A Randomized Prospective Study of Early Intensification Versus Alternating Triple Therapy for Patients With Poor Prognosis Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation&#xD;
      may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare the effectiveness of two regimens of&#xD;
      combination chemotherapy in treating patients who have intermediate-grade or immunoblastic&#xD;
      lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the efficacy of early intensification vs alternating triple chemotherapy in&#xD;
           patients with intermediate-grade or immunoblastic lymphoma with poor prognostic&#xD;
           features.&#xD;
&#xD;
        -  Compare, in a prospective manner, the cost/benefit ratio of these regimens in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine the value of monitoring minimal residual disease detection via in vitro&#xD;
           culture methods and polymerase chain reaction analysis of peripheral stem cell apheresis&#xD;
           products and by longitudinal monitoring of blood and bone marrow samples in these&#xD;
           patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized study. Patients are stratified according to tumor score (3 or 4&#xD;
      vs 5 or 6).&#xD;
&#xD;
      During the first course of induction, patients receive IDSHAP comprising idarubicin (IDA) and&#xD;
      cisplatin IV continuously on days 1-4, cytarabine (ARA-C) IV over 2 hours on day 5, and&#xD;
      methylprednisolone (MePRDL) IV over 15 minutes on days 1-5. During the second course of&#xD;
      induction, patients receive MBIDCOS comprising vincristine, bleomycin, and cyclophosphamide&#xD;
      IV over 15 minutes on day 1, IDA IV continuously and MePRDL IV over 15 minutes on days 1-3,&#xD;
      methotrexate (MTX) IV over 2 hours on day 10, and oral leucovorin calcium every 6 hours on&#xD;
      days 11 and 12. Each course lasts 3 weeks in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Patients with stable or responding disease after induction are randomized to 1 of 2 treatment&#xD;
      arms.&#xD;
&#xD;
      Arm I&#xD;
&#xD;
        -  Patients receive the following 3 courses of early intensification.&#xD;
&#xD;
             -  First course: Patients receive ifosfamide (IFF) IV continuously and etoposide&#xD;
                (VP-16) IV over 2 hours every 12 hours on days 1-3. Filgrastim (G-CSF) is&#xD;
                administered subcutaneously (SC) beginning on day 5 and continuing until blood&#xD;
                counts recover and then autologous peripheral blood stem cells (PBSC) are&#xD;
                harvested, selected for CD34 positive cells, and purged in vitro. If more than 5%&#xD;
                of the WBC contains lymphoma cells after induction, then 2 courses of IFF and VP-16&#xD;
                are administered before PBSC harvest.&#xD;
&#xD;
             -  Second course: Patients receive IFF IV continuously on days 1-3, mitoxantrone&#xD;
                (DHAD) IV on day 1, and G-CSF SC as in the first course.&#xD;
&#xD;
             -  Third course: Patients receive carmustine IV over 1 hour on day -6, ARA-C and VP-16&#xD;
                IV every 12 hours on days -5 to -2, and melphalan IV on day -1. PBSC are reinfused&#xD;
                on day 0. G-CSF is administered SC beginning on day 0 and continuing until blood&#xD;
                counts recover. Each course lasts 3 weeks in the absence of disease progression or&#xD;
                unacceptable toxicity.&#xD;
&#xD;
      Arm II&#xD;
&#xD;
        -  Patients receive IDSHAP during courses 2 and 5, MBIDCOS during courses 3 and 6, and IFF&#xD;
           and VP-16 IV over 1 hour on days 1-3 and DHAD IV over 15 minutes on day 1 during courses&#xD;
           1, 4, and 7. Each course lasts 4 weeks in the absence of disease progression or&#xD;
           unacceptable toxicity.&#xD;
&#xD;
      Patients with residual disease after completion of arm I or II treatment undergo radiotherapy&#xD;
      to areas of bulk disease if feasible. Patients on both arms with meningeal involvement&#xD;
      receive ARA-C intrathecally (IT) alternated with MTX every other day until 1 week after&#xD;
      clearing of CNS disease and then 2 IT injections during every course of chemotherapy&#xD;
      thereafter. Patients with divergent histology who achieve complete response after completion&#xD;
      of arm I or II treatment receive interferon alfa 3 times a week for 1 year.&#xD;
&#xD;
      Patients are followed at 1 month, every 3 months for 1 year, every 6 months for 1 year, and&#xD;
      then annually for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 136 patients will be accrued for this study within 4 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 30, 1995</start_date>
  <completion_date type="Actual">February 4, 2004</completion_date>
  <primary_completion_date type="Actual">February 4, 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of Early Intensification vs. Alternating Triple Chemotherapy</measure>
    <time_frame>Monthly</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 courses of early intensification:&#xD;
First course: Ifosfamide (IFF) IV continuously and Etoposide (VP-16) IV over 2 hours every 12 hours on days 1-3. Filgrastim (G-CSF) administered subcutaneously (SC) beginning on day 5 and continuing until blood counts recover then autologous peripheral blood stem cells (PBSC) are harvested, selected for CD34 positive cells, and purged in vitro. If more than 5% of the WBC contains lymphoma cells after induction, then 2 courses of IFF and VP-16 are administered before PBSC harvest.&#xD;
Second course: IFF IV continuously on days 1-3, mitoxantrone (DHAD) IV on day 1, and G-CSF SC as in first course.&#xD;
Third course: Carmustine IV over 1 hour on day -6, ARA-C and VP-16 IV every 12 hours on days -5 to -2, and melphalan IV on day -1. PBSC are reinfused on day 0. G-CSF is administered SC beginning on day 0 and continuing until blood counts recover. Each course lasts 3 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IDSHAP during 4 week courses 2 and 5, MBIDCOS during courses 3 and 6, and IFF and VP-16 IV over 1 hour on days 1-3 and DHAD IV over 15 minutes on day 1 during courses 1, 4, and 7.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bleomycin Sulfate (BLM)</intervention_name>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>Blenoxane</other_name>
    <other_name>BLM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Filgrastim (G-CSF)</intervention_name>
    <description>Arm 1: Administered subcutaneously (SC) beginning on day 5 and continuing until blood counts recover through Course 1 then 2 courses administered before PBSC harvest and same regimen with Course 2, then daily with Day 0 of infusion.</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant Interferon Alfa</intervention_name>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carmustine</intervention_name>
    <description>Arm 1, Course 3, IV over 1 hour on day -6.</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>BiCNU</other_name>
    <other_name>BiCNUI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin (CDDP)</intervention_name>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>Platinol</other_name>
    <other_name>Platinol-AQ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine (ARA-C)</intervention_name>
    <description>Arm 1, Course 3, every 12 hours on days -5 to -2.</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>ARA-C</other_name>
    <other_name>Cytosar</other_name>
    <other_name>DepotCyt</other_name>
    <other_name>Cytosine arabinosine hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide (VP-16)</intervention_name>
    <description>Course 1, IV over 2 hours every 12 hours on days 1-3; Course 3, every 12 hours on days -5 to -2.</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>VePesid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idarubicin</intervention_name>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>Idamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
    <description>During Course 1, IV continuously; Course 2, IV continuously on days 1-3.</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>Ifex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin Calcium</intervention_name>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>Leucovorin</other_name>
    <other_name>Citrovorum</other_name>
    <other_name>Wellcovorin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>Depo-Medrol</other_name>
    <other_name>Medrol</other_name>
    <other_name>Solu-Medrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitoxantrone hydrochloride (DHAD)</intervention_name>
    <description>Arm 1, Course 2, IV on day 1.</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>mitoxantrone</other_name>
    <other_name>Novantrone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine Sulfate</intervention_name>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Transplantation</intervention_name>
    <description>Infusion of stem cells on Day 0.</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>autologous peripheral blood stem cells</other_name>
    <other_name>PBSC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>RT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of previously untreated intermediate-grade or immunoblastic lymphoma&#xD;
&#xD;
               -  Tumor score of 3 or greater, defined by the presence of 3 or more of the&#xD;
                  following criteria :&#xD;
&#xD;
                    -  Ann Arbor stage III or IV disease&#xD;
&#xD;
                    -  B symptoms (fever, sweats, and weight loss greater than 10%)&#xD;
&#xD;
                    -  At least 1 tumor mass greater than 7 cm or mediastinal mass visible on plain&#xD;
                       chest x-ray&#xD;
&#xD;
                    -  Beta-2 microglobulin at least 3.0&#xD;
&#xD;
                    -  Lactic dehydrogenase at least 1.1 times the upper limit of normal&#xD;
&#xD;
          -  T- and B-cell lymphomas allowed if intermediate grade or immunoblastic&#xD;
&#xD;
          -  Divergent histologies, including bone marrow involvement, allowed&#xD;
&#xD;
          -  CNS involvement allowed NOTE: A new classification scheme for adult non-Hodgkin's&#xD;
             lymphoma has been adopted by PDQ. The terminology of &quot;indolent&quot; or &quot;aggressive&quot;&#xD;
             lymphoma will replace the former terminology of &quot;low&quot;, &quot;intermediate&quot;, or &quot;high&quot; grade&#xD;
             lymphoma. However, this protocol uses the former terminology.&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  15 to 59&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 2.0 mg/dL (unless elevation due to lymphoma)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL (unless elevation due to lymphoma)&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  LVEF greater than 50% by echocardiogram if over age 45&#xD;
&#xD;
          -  No congestive heart failure, angina, history of myocardial infarction, or arrhythmia&#xD;
             unless cleared by principal investigator after cardiology consultation&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No history of chronic obstructive or restrictive lung disease&#xD;
&#xD;
          -  Pulmonary consultation required for smokers or patients with questionable lung&#xD;
             function&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No prior malignancy with poor prognosis (less than 90% probability of surviving for 5&#xD;
             years)&#xD;
&#xD;
          -  No geographic, economic, emotional, or social condition that would preclude study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No prior biologic therapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No prior endocrine therapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard E. Champlin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>April 15, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2003</study_first_posted>
  <last_update_submitted>November 13, 2018</last_update_submitted>
  <last_update_submitted_qc>November 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I grade 3 follicular lymphoma</keyword>
  <keyword>stage I adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage I adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage I adult diffuse large cell lymphoma</keyword>
  <keyword>stage I adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Bleomycin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

